Companion Diagnostics: The CDx Co-Development Process | Diagnostics Market Intelligence

Description

List of Tables

A companion diagnostic is the only medical device whose market is created by someone else's label. When a targeted cancer drug wins approval gated on a biomarker, the test that reads the biomarker becomes infrastructure overnight - and in Japan, that test must clear its own approval, its own reimbursement, and its own delivery network, ideally on the same day the drug launches. The co-development process that synchronizes a drug program with a diagnostic program is therefore one of the most consequential, least documented disciplines in oncology commercialization. Japan's version has its own grammar: PMDA reviews drug and test in parallel but separately, the CDx concept is embedded in guidance rather than statute, and the reimbursement decision follows a price-formation process with no exact Western analogue.

The field's history in Japan is short enough to read as a sequence of precedents. The Oncomine Dx Target Test became the first multi-marker companion diagnostic approved in the country in 2017. FoundationOne CDx followed, then Guardant360 CDx brought liquid biopsy into the reimbursed system, and the domestically built OncoGuide NCC Oncopanel demonstrated a Japanese co-development model between industry and the National Cancer Center. Each case solved different synchronization problems - bridging from clinical-trial assays, sample availability, evidence thresholds - and each left lessons sponsors still cite. What remains genuinely hard has not changed: drug timelines slip, diagnostic partners change, biomarker prevalence in Japanese populations must be documented, and a mismatch of months between drug and test approval can strand a launch.

This report documents the process as practiced. It explains the regulatory and reimbursement machinery, walks the co-development sequence from partner selection through bridging studies to simultaneous submission, and reconstructs the landmark approvals as case studies with their specific lessons. Practical chapters cover contracts, budgets, post-approval change management, and lifecycle expansion as CDx labels accumulate indications. The audience is foreign oncology sponsors planning Japan programs, IVD companies structuring partnerships, and the regulatory and market-access professionals who run the synchronization.

Scope and Coverage: The report covers the companion diagnostic co-development process in Japan: regulatory framework, reimbursement pathway, landmark case studies, operational mechanics, and lifecycle management. Comparative reference covers US and EU CDx practice.

Report Highlights:

PMDA's parallel review structure for drugs and companion diagnostics
Case studies: Oncomine Dx, FoundationOne CDx, Guardant360 CDx, and OncoGuide NCC Oncopanel
Co-development sequencing from partner selection to simultaneous submission
Bridging study design and Japanese-population evidence requirements
NHI price formation for companion diagnostics under the C1/C2/C3 system
Lifecycle management as CDx labels accumulate drug indications

Product Code: JPH-056

Table of Content

1. Executive Summary

2. Companion Diagnostics: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

Thermo Fisher Scientific (US) - Oncomine Dx Target Test, first multi-marker CDx approved in Japan (2017). Foundation Medicine/Roche (CH) - FoundationOne CDx approved (2018) and reimbursed (2019) in Japan. Guardant Health (US) - Guardant360 CDx approved (2021) and reimbursed (2022) in Japan. Sysmex (JP) - OncoGuide NCC Oncopanel co-development with the National Cancer Center. Qiagen (DE) - therascreen EGFR, KRAS, and FGFR CDx assays tied to drug approvals. AmoyDx (CN) - Pan Lung Cancer PCR panel approved in Japan (2021). Agilent/Dako (US) - PD-L1 IHC 22C3 and 28-8 pharmDx CDx for checkpoint inhibitors. Roche/Ventana (CH) - PD-L1 SP263 and SP142 IHC companion diagnostics. Abbott (US) - FISH-based CDx heritage in HER2 and ALK testing. ArcherDX/Invitae (US) - personalized cancer monitoring and CDx co-development services. Chugai (JP) - Japan-side sponsor counterpart for Roche-tied CDx approvals. Daiichi Sankyo (JP) - drug sponsor requiring HER2 and TROP2 CDx co-development for DXd ADCs.

Product Code: JPH-056

List of Tables

Table 1. Companion diagnostic definition and regulatory status in Japan
Table 2. PMDA CDx approval pathway structure
Table 3. Drug-diagnostic co-approval synchronization mechanics
Table 4. CDx labeling and intended-use structure in Japan
Table 5. Set approval versus individual approval distinctions
Table 6. Post-approval change management for CDx
Table 7. International CDx framework comparison: Japan, US, EU
Table 8. Oncomine Dx Target Test: first multi-marker CDx approval (2017)
Table 9. FoundationOne CDx approval (2018) and reimbursement (2019)
Table 10. Guardant360 CDx approval (2021) and reimbursement (2022)
Table 11. OncoGuide NCC Oncopanel domestic co-development model
Table 12. Qiagen therascreen franchise in Japan
Table 13. Roche cobas single-gene CDx portfolio in Japan
Table 14. Agilent and Dako IHC companion diagnostics in Japan
Table 15. HER2 IHC and FISH CDx heritage in gastric and breast cancer
Table 16. MSI and TMB companion diagnostic approvals
Table 17. CDx partner selection criteria for oncology sponsors
Table 18. Development timeline synchronization between drug and device programs
Table 19. Bridging study design from clinical trial assay to CDx
Table 20. Analytical validation requirements for Japanese CDx
Table 21. Clinical validation using Japanese trial samples
Table 22. Biomarker prevalence documentation for Japanese populations
Table 23. Sample banking and retesting strategies
Table 24. Risk management for drug-device timeline mismatch
Table 25. NHI reimbursement process for companion diagnostics
Table 26. C1/C2/C3 classification applied to CDx
Table 27. Panel CDx versus single-marker test pricing
Table 28. Testing infrastructure requirements for CDx delivery
Table 29. Reference laboratory and hospital laboratory roles
Table 30. Turnaround time management for treatment decisions
Table 31. Tissue-liquid complementarity in CDx strategies
Table 32. Access disparities in CDx availability across regions
Table 33. Pre-development consultation strategy with PMDA
Table 34. CDx budget and timeline planning framework
Table 35. Contract structures between drug and diagnostic partners
Table 36. Regulatory documentation requirements for CDx submissions
Table 37. Common deficiency themes in CDx reviews
Table 38. Post-marketing surveillance obligations for CDx
Table 39. Lifecycle management: adding drug indications to CDx labels
Table 40. Multi-drug CDx expansion strategy
Table 41. Emerging biomarker classes requiring companion diagnostics
Table 42. MRD and monitoring claims as a CDx frontier
Table 43. IHC-to-NGS transition management
Table 44. AI-read pathology companion diagnostic status
Table 45. Liquid biopsy CDx expansion trajectory
Table 46. Harmonization efforts across jurisdictions
Table 47. CDx market structure and vendor shares framework in Japan
Table 48. Entrant opportunities in CDx development and services
Table 49. Watchlist of pending CDx decisions
Table 50. Report methodology and evidence sources

List of Figures

Figure 1. CDx concept and regulatory positioning in Japan
Figure 2. PMDA CDx review pathway flowchart
Figure 3. Drug-diagnostic synchronization timeline
Figure 4. CDx label structure schematic
Figure 5. Set versus individual approval map
Figure 6. Post-approval change management flow
Figure 7. Japan-US-EU CDx framework comparison
Figure 8. Oncomine Dx approval case anatomy
Figure 9. FoundationOne CDx case anatomy
Figure 10. Guardant360 CDx case anatomy
Figure 11. OncoGuide co-development model diagram
Figure 12. therascreen franchise map
Figure 13. cobas CDx portfolio map
Figure 14. IHC CDx landscape in Japan
Figure 15. HER2 CDx heritage pathway
Figure 16. MSI and TMB CDx approval map
Figure 17. Partner selection criteria framework
Figure 18. Synchronization mechanics between drug and device timelines
Figure 19. Bridging study design schematic
Figure 20. Analytical validation requirement map
Figure 21. Japanese clinical validation workflow
Figure 22. Biomarker prevalence documentation structure
Figure 23. Sample banking strategy map
Figure 24. Timeline mismatch risk framework
Figure 25. NHI reimbursement flow for CDx
Figure 26. C1/C2/C3 classification decision tree for CDx
Figure 27. Panel versus single-marker pricing structure
Figure 28. Testing infrastructure requirement map
Figure 29. Reference versus hospital laboratory role map
Figure 30. Turnaround time management flow
Figure 31. Tissue-liquid strategy framework
Figure 32. Regional access disparity map for CDx
Figure 33. PMDA consultation strategy flow
Figure 34. CDx budget and timeline framework
Figure 35. Drug-diagnostic contract structure taxonomy
Figure 36. CDx documentation requirement map
Figure 37. Deficiency theme map from reviews
Figure 38. Post-marketing obligation structure
Figure 39. Lifecycle expansion pathway for CDx labels
Figure 40. Multi-drug CDx strategy map
Figure 41. Emerging biomarker class map
Figure 42. MRD-as-CDx frontier schematic
Figure 43. IHC-to-NGS transition framework
Figure 44. AI pathology CDx status map
Figure 45. Liquid biopsy CDx trajectory
Figure 46. Harmonization initiative map
Figure 47. CDx market structure map
Figure 48. Entrant opportunity map in CDx
Figure 49. Pending CDx decision watchlist
Figure 50. Report methodology schematic

Companion Diagnostics: The CDx Co-Development Process | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Companion Diagnostics: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures